Jodi Devlin's most recent trade in TriSalus Life Sciences Inc was a trade of 1,772 Common Stock done at an average price of $4.1 . Disclosure was reported to the exchange on March 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Sale of securities on an exchange or to another person at price $ 4.09 per share. | 11 Mar 2026 | 1,772 | 97,637 | - | 4.1 | 7,247 | Common Stock |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Sale of securities on an exchange or to another person at price $ 4.13 per share. | 11 Mar 2026 | 1,162 | 99,409 | - | 4.1 | 4,799 | Common Stock |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Sale of securities on an exchange or to another person at price $ 4.12 per share. | 11 Mar 2026 | 273 | 97,364 | - | 4.1 | 1,125 | Common Stock |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Nov 2025 | 100,000 | 463,750 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Nov 2025 | 50,000 | 100,571 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 19 May 2025 | 24,131 | 57,528 | - | 5.2 | 124,999 | Common Stock |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Sale of securities on an exchange or to another person at price $ 5.18 per share. | 19 May 2025 | 4,764 | 52,764 | - | 5.2 | 24,678 | Common Stock |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of Clinical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 5,272 | 33,397 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of COMMERC. OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 63,750 | 63,750 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Jodi Devlin | Chief of COMMERC. OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 10,625 | 28,125 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Jodi Devlin | PRESIDENT, COMMERC. OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 105,000 | 105,000 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Jodi Devlin | PRESIDENT, COMMERC. OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 17,500 | 17,500 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Jodi Devlin | President, Therapeutics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2023 | 195,000 | 195,000 | - | - | Employee Stock Option (right to buy) |